<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02198248</url>
  </required_header>
  <id_info>
    <org_study_id>G25051</org_study_id>
    <secondary_id>UMIN000014222</secondary_id>
    <nct_id>NCT02198248</nct_id>
  </id_info>
  <brief_title>Low-dose Glucocorticoid Vasculitis Induction Study</brief_title>
  <acronym>LoVAS</acronym>
  <official_title>Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiba University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Hospital Organization Chiba East Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chiba University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous reports suggested conventional immunosuppressants such as cyclophosphamide could not
      reduce glucocorticoid dose in remission induction in ANCA-associated vasculitis because of
      lower remission rate and higher relapse rate. However those reports didn't include rituximab.

      B cell depletion therapy by rituximab is a new strategy for remission induction in
      ANCA-associated vasculitis. The RAVE and RITUXVAS trial (NEJM 2010, both) showed high-dose
      glucocorticoid plus rituximab had roughly the same efficacy and safety as high-dose
      glucocorticoid plus IV-cyclophosphamide. In addition, recent retrospective observational
      studies reported low-dose glucocorticoid plus rituximab led to re-induction in severe
      relapsing ANCA-associated vasculitis.

      Thus, the investigators aim to investigate whether rituximab can reduce glucocorticoid dose
      in induction remission in ANCA-associated vasculitis (to show non-inferiority for efficacy
      between low-dose and high-dose glucocorticoid plus rituximab). Participants will be
      randomised to the &quot;low-dose glucocorticoid plus rituximab&quot; or the high-dose glucocorticoid
      plus rituximab&quot; groups. Primary endpoint is proportion of remission at 6 months, then data
      regarding relapse and long-term safety will be collected until 24 months.

      The study has been designed by the principal and coordinating investigators. It will include
      140 participants from 18 hospitals in Japan. It is funded by Chiba University Hospital and
      Chiba East Hospital.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis is characterised by small
      vessel vasculitis and presence of autoantibodies, ANCA. It can be a life-threatening disease
      with renal/respiratory failure. Current standard therapy in induction remission for
      ANCA-associated vasculitis is combination of high-dose glucocorticoid and
      IV-cyclophosphamide. This regimen is effective (remission rate; 80-90%), but often cause
      various glucocorticoid-related side effects. Especially, infection is related to death. Thus
      a new regimen reducing glucocorticoid dose is required.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of the patients achieving remission</measure>
    <time_frame>6 months</time_frame>
    <description>Remission; BVAS ver.3=0 (or 1 with only one minor and persistent BVAS item) and prednisolone &lt;10mg/day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to remission</measure>
    <time_frame>assessed at 1, 2, 4 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival, disease free survival, time to end-stage renal disease, time to the first serious adverse event</measure>
    <time_frame>0-24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of death, relapse, end-stage renal disease and the composite of these</measure>
    <time_frame>at 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of severe relapse</measure>
    <time_frame>at 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birmingham Vasculitis Activity Score (BVAS) version 3</measure>
    <time_frame>assessed at 0, 1, 2, 4, 6, 9, 12, 18 and 24 months</time_frame>
    <description>BVAS is a scoring system for assessing disease activity of vasculitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasculitis Damage Index (VDI)</measure>
    <time_frame>assessed at 0, 6, 12, 18 and 24 months</time_frame>
    <description>VDI is a scoring system for assessing irreversible disease damage due to vasculitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-Form 36 (SF-36)</measure>
    <time_frame>assessed at 0, 6, 12, 18 and 24 months</time_frame>
    <description>SF-36 is a scoring system for assessing patient QOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global assessment (visualised analogue scale)</measure>
    <time_frame>assessed at 0, 6, 12, 18 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulative dose of glucocorticoids</measure>
    <time_frame>assessed at 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of events of adverse events/serious adverse events, proportions of the patients with adverse events/serious adverse events</measure>
    <time_frame>at 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of the patients with new onset diabetes mellitus</measure>
    <time_frame>at 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of the patients with new onset insomnia</measure>
    <time_frame>at 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of the patients with new onset bone fracture, bone density</measure>
    <time_frame>at 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infections, proportions of the patients with infection</measure>
    <time_frame>at 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of the patients with new onset hypertension</measure>
    <time_frame>at 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of the patients with new onset hyperlipidemia</measure>
    <time_frame>at 6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients achieving remission and discontinuance of glucocorticoids</measure>
    <time_frame>at 6 and 24 months</time_frame>
    <description>Remission is BVAS ver3=0 and prednisolone &lt;10mg/day.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum immunoglobulin levels</measure>
    <time_frame>assessed at 0, 1, 2, 4, 6, 9, 12, 18 and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peripheral blood B cell counts</measure>
    <time_frame>assessed at 0, 1, 2, 4, 6, 9, 12, 18 and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum MPO-/PR3-ANCA levels measured by ELISA</measure>
    <time_frame>assessed at 0, 1, 2, 4, 6, 9, 12, 18 and 24 months</time_frame>
    <description>MPO-ANCA and PR3-ANCA are disease specific autoantibodies binding neutrophil cytoplasmic antigen.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</condition>
  <condition>Microscopic Polyangiitis</condition>
  <condition>Wegener Granulomatosis</condition>
  <arm_group>
    <arm_group_label>Low-dose glucocorticoid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisolone will be commenced with dose of 0.5mg/kg/day and will be tapered and off within 6 months. If a patient fails to achieve BVAS=0, an investigator can postpone the procedure of stopping prednisolone (prednisolone 5mg/day x 2 weeks, 4mg/day x 2 weeks, 3mg/day x 4 weeks, 2mg/day x 4 weeks, 1mg/day x 4 weeks, then off prednisolone). Once starting the procedure, prednisolone must be off after 16 weeks. Patients will also receive rituximab (375mg/m2/w x4).
After achieving remission, patients will be receive rituximab (1g/body or 0.5g/bodyx2) every 6 months as remission maintenance therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose glucocorticoid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone will be commenced with dose of 1.0mg/kg/day and will be tapered to 10mg/day within 6 months. Patients will also receive rituximab (375mg/m2/w x4).
After achieving remission, patients will be receive rituximab (1g/body or 0.5g/bodyx2) every 6 months as remission maintenance therapy. There's no limitation by the protocol regarding further prednisolone tapering.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Patients will be administered rituximab (375mg/m2/w x4 infusions) for reducing glucocorticoid dose in remission induction phase.</description>
    <arm_group_label>Low-dose glucocorticoid</arm_group_label>
    <arm_group_label>High-dose glucocorticoid</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucocorticoids</intervention_name>
    <description>&quot;Low-dose&quot; group commenced 0.5mg/kg/day, then taper and stop within 6 months following pre-defined schedule.
&quot;High-dose&quot; group commenced 1.0mg/kg/day, then taper to 10mg/day within 6 months following pre-defined schedule.</description>
    <arm_group_label>Low-dose glucocorticoid</arm_group_label>
    <arm_group_label>High-dose glucocorticoid</arm_group_label>
    <other_name>Predonine</other_name>
    <other_name>Prednisolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of written informed consent by a patient or a surrogate decision maker

          2. Age=&gt;20 years

          3. New clinical diagnosis of ANCA-associated vasculitis (granulomatosis with
             polyangiitis, microscopic polyangiitis or renal limited ANCA-associated vasculitis)
             consistent with the 2012 Chapel Hill consensus definitions

          4. Positive test by ELISA for proteinase 3-ANCA or myeloperoxidase-ANCA

        Exclusion Criteria:

          1. Prior treatment for ANCA-associated vasculitis before trial entry

          2. ANCA-associated vasculitis related glomerulonephritis (eGFR&lt;15ml/min) or alveolar
             hemorrhage (oxygen inhalation &gt;2L/min)

          3. Presence of another multisystem autoimmune disease

          4. Known infection with HIV; a past or current history of hepatitis B virus or hepatitis
             C virus infection

          5. Desire to bear children, pregnancy or lactating

          6. History of malignancy within the past 5 years or any evidence of persistent malignancy

          7. Ongoing or recent (last 1 year) evidence of active tuberculosis

          8. Severe allergy or anaphylaxis to monoclonal antibody therapy

          9. Any concomitant condition anticipated to likely require oral systemic glucocorticoids,
             immunosuppressants, biologics, plasma exchange or IVIg

         10. Any biological B cell depleting agent (such as rituximab or belimumab) within the past
             6 months

         11. Other conditions, in the investigator's opinion, inappropriate for the trial entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroshi Nakajima, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chiba University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shunsuke Furuta, M.D., Ph.D</last_name>
    <phone>+81 43-222-7171</phone>
    <phone_ext>5531</phone_ext>
    <email>shfuruta@chiba-u.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asahi General Hospital</name>
      <address>
        <city>Asahi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shinichiro Kagami, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Shinichiro Kagami, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Teikyo University Medical Centre</name>
      <address>
        <city>Ichihara</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noboru Hagino, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Noboru Hagino, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kameda Medical Centre</name>
      <address>
        <city>Kamogawa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shinji Motoshima, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Shinsji Motoshima, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Matsudo City Hospital</name>
      <address>
        <city>Matsudo</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsuyoshi Umibe, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Tsuyoshi Umibe, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saiseikai Narashino Hospital</name>
      <address>
        <city>Narashino</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasushi Nawata, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Yasushi Nawata, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Narita Hospital</name>
      <address>
        <city>Narita</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masaki Hiraguri, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Masaki Hiraguri, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juntendo University Urayasu Hospital</name>
      <address>
        <city>Urayasu</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iwao Sekikawa, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Iwao Sekikawa, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shinji Morimoto, M.D., Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Yachiyo Medical Center</name>
      <address>
        <city>Yachiyo</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yohei Seto, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Yohei Seto, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shimoshizu Hospital</name>
      <address>
        <city>Yotsukaido</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takao Sugiyama, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Takao Sugiyama, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Occupational and Environmental Health</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshiya Tanaka, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hokkaido University</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatsuya Atsumi, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hitachinaka General Hospital</name>
      <address>
        <city>Katsuta</city>
        <state>Ibaragi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taichi Hayashi, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Taichi Hayashi, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaragi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takayuki Sumida, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Takayuki Sumida, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Atsuhiro Kondo, M.D., Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Marianna University School of Medicine Hospital</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hidehiro Yamada, M.D., Ph.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Mamiko Shimizu</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Yokohama City University</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshiaki Ishigatsubo, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Yoshiaki Ishigatsubo, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryusuke Yoshimi, M.D., Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yokohama Rosai Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasuhiko Kita, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Yasuhiko Kita, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tohoku</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomonori Ishii, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shinshu University</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuichi Ikeda, M.D., Ph.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Yasuhiro Shimojima, M.D., Ph.D.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Saitama Medical Center</name>
      <address>
        <city>Kawagoe</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kouichi Amano, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Kouichi Amano, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryota Sakai, M.D., Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dokkyo Medical University</name>
      <address>
        <city>Mibu</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuhiro Kurasawa, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Kazuhiro Kurasawa, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Takayoshi Owada, M.D., Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Teikyo University</name>
      <address>
        <city>Itabashi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hajime Kono, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Hajime Kono, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shunya Uchida, M.D., Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Shinanomachi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsutomu Takeuchi, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akita University</name>
      <address>
        <city>Akita</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atsushi Komatsuda, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shunsuke Furuta, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Shunsuke Furuta, M.D., Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hiroshi Nakajima, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kei Ikeda, M.D., Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chiba Aoba Municipal Hospital</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshihisa Kobayashi, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Yoshihisa Kobayashi, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chiba East Hospital</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryutaro Matsumura, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Ryutaro Matsumura, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroshi Watanabe, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Hiroshi Watanabe, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nagasaki University</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atsushi Kawakami, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niigata University</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ichiei Narita, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Ichiei Narita, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka University</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atsushi Kumanogoh, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Center for Global Health and Medicine</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Akio Mimori, M.D., Ph.D</last_name>
    </contact>
    <investigator>
      <last_name>Akio Mimori, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hiroshi Kaneko, M.D., Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, Plaisance M, Pusey CD, Jayne DR; Pan-Thames Renal Research Group. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003 Apr;41(4):776-84. Review.</citation>
    <PMID>12666064</PMID>
  </reference>
  <reference>
    <citation>de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO; EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009 May 19;150(10):670-80.</citation>
    <PMID>19451574</PMID>
  </reference>
  <reference>
    <citation>De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005 Aug;52(8):2461-9.</citation>
    <PMID>16052573</PMID>
  </reference>
  <reference>
    <citation>Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, van der Woude FJ, de Lind van Wijngaarden RA, Pusey CD; European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007 Jul;18(7):2180-8. Epub 2007 Jun 20.</citation>
    <PMID>17582159</PMID>
  </reference>
  <reference>
    <citation>Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med. 1971 Dec 30;285(27):1493-6.</citation>
    <PMID>5127139</PMID>
  </reference>
  <reference>
    <citation>Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol. 1999 May;103(5 Pt 1):885-94.</citation>
    <PMID>10329824</PMID>
  </reference>
  <reference>
    <citation>Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221-32. doi: 10.1056/NEJMoa0909905.</citation>
    <PMID>20647199</PMID>
  </reference>
  <reference>
    <citation>Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010 Jul 15;363(3):211-20. doi: 10.1056/NEJMoa0909169.</citation>
    <PMID>20647198</PMID>
  </reference>
  <reference>
    <citation>Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, Ferraccioli G, Gottenberg JE, Isaacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, van der Heijde D, van Vollenhoven RF, Emery P; Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011 Jun;70(6):909-20. doi: 10.1136/ard.2010.144998. Epub 2011 Mar 6.</citation>
    <PMID>21378402</PMID>
  </reference>
  <reference>
    <citation>Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer. 2007 Jun 1;109(11):2182-9.</citation>
    <PMID>17429839</PMID>
  </reference>
  <reference>
    <citation>Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res (Hoboken). 2010 Aug;62(8):1166-73. doi: 10.1002/acr.20176.</citation>
    <PMID>20235186</PMID>
  </reference>
  <reference>
    <citation>Wada T, Hara A, Arimura Y, Sada KE, Makino H; Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan. Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. J Rheumatol. 2012 Mar;39(3):545-51. doi: 10.3899/jrheum.110705. Epub 2011 Dec 15.</citation>
    <PMID>22174198</PMID>
  </reference>
  <reference>
    <citation>Furuta S, Chaudhry AN, Hamano Y, Fujimoto S, Nagafuchi H, Makino H, Matsuo S, Ozaki S, Endo T, Muso E, Ito C, Kusano E, Yamagata M, Ikeda K, Kashiwakuma D, Iwamoto I, Westman K, Jayne D. Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J Rheumatol. 2014 Feb;41(2):325-33. doi: 10.3899/jrheum.130602. Epub 2014 Jan 15.</citation>
    <PMID>24429174</PMID>
  </reference>
  <reference>
    <citation>Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, Smith KG, Jayne DR. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012 Nov;64(11):3760-9. doi: 10.1002/art.34583.</citation>
    <PMID>22729997</PMID>
  </reference>
  <reference>
    <citation>Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. doi: 10.1002/art.37715.</citation>
    <PMID>23045170</PMID>
  </reference>
  <reference>
    <citation>Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, Adu D. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997 Feb;40(2):371-80.</citation>
    <PMID>9041949</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2014</study_first_submitted>
  <study_first_submitted_qc>July 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2014</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chiba University</investigator_affiliation>
    <investigator_full_name>Shunsuke Furuta</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
    <mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

